Lupin Q2 Results: Net profit soars 74% YoY to Rs 853 crore on strong demand for generic drugs
Lupin reported a bigger-than-expected rise in second-quarter profit on Thursday, driven by strong demand for its respiratory and diabetes management drugs.
Consolidated net profit of the company, which makes biosimilars and active pharmaceutical ingredients, rose to 8.53 billion rupees (about $101 million) for the quarter ended Sept. 30, up about 74% from a year earlier and higher than analysts' estimates of 7.29 billion rupees, as per data compiled by LSEG.
Revenue from operations grew 11.3% to 54.97 billion rupees.
Indian generic drugmakers earn a significant share of their revenue from the U.S., which is the world's biggest pharmaceutical market.
Larger rivals Cipla and Sun Pharma beat their second-quarter profit estimates on strong demand in the U.S.
Stock Trading
Algo Trading Made Easy
By — Vivek Gadodia, Partner at Dravyaniti Consulting and RBT Algo Systems
Stock Trading
A2Z of Stock Trading — Online Stock Trading Course
By — elearnmarkets, Financial Education by StockEdge
Stock Trading
Technical Analysis for Everyone — Technical Analysis Course
By — Abhijit Paul, Technical Research Head, Fund Manager- ICICI Securities
Stock Trading
Commodity Markets Made Easy: Commodity Trading Course
By — elearnmarkets, Financial Education by StockEdge
Stock Trading
Ichimoku Trading Unlocked: Expert Analysis and Strategy
By — Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert
Stock Trading
RSI Trading Techniques: Mastering the RSI Indicator
By — Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology
